Trevi Therapeutics, Inc. Employee Directory

Biotechnology ResearchConnecticut, United States11-50 Employees

Trevi Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for chronic cough associated with respiratory and neurologic conditions. Its lead product, Haduvio, is an oral extended-release formulation of nalbuphine designed to act on the cough reflex both centrally and peripherally, aiming to provide a significant reduction in cough frequency for patients with idiopathic pulmonary fibrosis, non-IPF interstitial lung disease, and refractory chronic cough. The company emphasizes its position in the field by pursuing an approach that targets opioid receptors involved in cough control, without scheduling concerns from the U.S. Drug Enforcement Administration. Trevi is based in New Haven, Connecticut, and operates within the biotechnology research sector, pursuing clinical development and early-stage trials for its investigational therapy.

Sign up for free to view info

Company overview Email format